Nasdaq · CIK 0000863894
VERU VERU INC.
Insider trading from SEC Form 4. Last filing May 6, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at VERU INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 22 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 4, 2026 | K Gary Barnette Chief Scientific Officer | AGrant or award Common Stock Optionderivative | +160,000 | $0.00 | $0 | 160,000 | May 6, 2026 |
| Dec 5, 2025 | K Gary Barnette Chief Scientific Officer | AGrant or award Common Stock Optionderivative | +27,000 | $0.00 | $0 | 27,000 | Dec 9, 2025 |
| Dec 5, 2025 | Harry Fisch Chief Corporate Officer | AGrant or award Common Stock Optionderivative | +27,000 | $0.00 | $0 | 27,000 | Dec 9, 2025 |
| Dec 5, 2025 | Michele Greco Chief Admin Officer and CFO | AGrant or award Common Stock Optionderivative | +27,000 | $0.00 | $0 | 27,000 | Dec 9, 2025 |
| Dec 5, 2025 | Grace Hyun director | AGrant or award Common Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Dec 9, 2025 |
| Dec 5, 2025 | Loren Mark Katzovitz director | AGrant or award Common Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Dec 9, 2025 |
| Dec 5, 2025 | Lucy Lu director | AGrant or award Common Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | Dec 9, 2025 |
| Dec 5, 2025 | Michael L Rankowitz director | AGrant or award Common Stock Optionderivative | +3,000 | $0.00 | $0 | 3,000 | Dec 9, 2025 |
| Dec 5, 2025 | Mitchell Shuster Steiner President and CEO | AGrant or award Common Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Dec 9, 2025 |
| Oct 1, 2025 | Michael L Rankowitz director | AGrant or award Common Stock Optionderivative | +7,000 | $0.00 | $0 | 7,000 | Oct 3, 2025 |
| Oct 1, 2025 | Lucy Lu director | AGrant or award Common Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Oct 3, 2025 |
| Oct 1, 2025 | Grace Hyun director | AGrant or award Common Stock Optionderivative | +3,000 | $0.00 | $0 | 3,000 | Oct 3, 2025 |
| May 6, 2025 | K Gary Barnette Chief Scientific Officer | AGrant or award Common Stock Optionderivative | +104,000 | $0.00 | $0 | 104,000 | May 8, 2025 |
| May 6, 2025 | Harry Fisch Chief Corporate Officer | AGrant or award Common Stock Optionderivative | +104,000 | $0.00 | $0 | 104,000 | May 8, 2025 |
| May 6, 2025 | Michele Greco Chief Admin Officer and CFO | AGrant or award Common Stock Optionderivative | +108,000 | $0.00 | $0 | 108,000 | May 8, 2025 |
| May 6, 2025 | Grace Hyun director | AGrant or award Common Stock Optionderivative | +55,000 | $0.00 | $0 | 55,000 | May 8, 2025 |
| May 6, 2025 | Loren Mark Katzovitz director | AGrant or award Common Stock Optionderivative | +90,000 | $0.00 | $0 | 90,000 | May 8, 2025 |
| May 6, 2025 | Lucy Lu director | AGrant or award Common Stock Optionderivative | +30,000 | $0.00 | $0 | 30,000 | May 8, 2025 |
| May 6, 2025 | Michael L Rankowitz director | AGrant or award Common Stock Optionderivative | +15,000 | $0.00 | $0 | 15,000 | May 8, 2025 |
| May 6, 2025 | Mitchell Shuster Steiner President and CEO | AGrant or award Common Stock Optionderivative | +378,000 | $0.00 | $0 | 378,000 | May 8, 2025 |
| Mar 13, 2025 | Grace Hyun director | AGrant or award Common Stock Optionderivative | +5,000 | $0.00 | $0 | 5,000 | Mar 14, 2025 |
| Mar 13, 2025 | Loren Mark Katzovitz director | AGrant or award Common Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Mar 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- K Gary BarnetteChief Scientific Officer
- Harry FischChief Corporate Officer
- Michele GrecoChief Admin Officer and CFO
- Grace Hyundirector
- Loren Mark Katzovitzdirector
- Lucy Ludirector
- Michael L Rankowitzdirector
- Mitchell Shuster SteinerPresident and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.